Engineered bacteria to accelerate wound healing: an adaptive, randomised, double-blind, placebo-controlled, first-in-human phase 1 trial

医学 耐受性 安慰剂 临床试验 伤口愈合 加药 生理盐水 随机对照试验 不利影响 外科 麻醉 内科学 病理 替代医学
作者
Emelie Öhnstedt,Evelina Vågesjö,Andreas E. R. Fasth,Hava Lofton Tomenius,Pia Dahg,Sofia Jönsson,Nisha Tyagi,Mikael Åström,Zhanar Myktybekova,Lovisa Ringstad,Margareth Jorvid,Peter Frank,Per Hedén,Stefan Roos,Mia Phillipson
出处
期刊:EClinicalMedicine [Elsevier BV]
卷期号:60: 102014-102014 被引量:24
标识
DOI:10.1016/j.eclinm.2023.102014
摘要

Summary

Background

Impaired wound healing is a growing medical problem and very few approved drugs with documented clinical efficacy are available. CXCL12-expressing lactic acid bacteria, Limosilactobacillus reuteri (ILP100-Topical), has been demonstrated to accelerate wound healing in controlled preclinical models. In this first-in-human study, the primary objective was to determine safety and tolerability of the drug candidate ILP100-Topical, while secondary objectives included assessments of clinical and biologic effects on wound healing by traditionally accepted methods and explorative and traceable assessments.

Methods

SITU-SAFE is an adaptive, randomised, double-blind, placebo-controlled, first-in-human phase 1 trial (EudraCT 2019-000680-24) consisting of a single (SAD) and a multiple ascending dose (MAD) part of three dose cohorts each. The study was performed at the Phase 1 Unit, Uppsala University Hospital, Uppsala, Sweden. Data in this article were collected between Sep 20th, 2019 and Oct 20th 2021. In total 240 wounds were induced on the upper arms in 36 healthy volunteers. SAD: 12 participants, 4 wounds (2/arm), MAD: 24 participants, 8 wounds (4/arm). Wounds in each participant were randomised to treatment with placebo/saline or ILP100-Topical.

Findings

In all individuals and doses, ILP100-Topical was safe and well-tolerated with no systemic exposure. A combined cohort analysis showed a significantly larger proportion of healed wounds (p = 0.020) on Day 32 by multi-dosing of ILP100-Topical when compared to saline/placebo (76% (73/96) and 59% (57/96) healed wounds, respectively). In addition, time to first registered healing was shortened by 6 days on average, and by 10 days at highest dose. ILP100-Topical increased the density of CXCL12+ cells in the wounds and local wound blood perfusion.

Interpretation

The favourable safety profile and observed effects on wound healing support continued clinical development of ILP100-Topical for the treatment of complicated wounds in patients.

Funding

Ilya Pharma AB (Sponsor), H2020 SME Instrument Phase II (#804438), Knut and Alice Wallenberg foundation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
晓风完成签到,获得积分10
3秒前
CR完成签到 ,获得积分10
4秒前
mammer应助超帅无色采纳,获得10
5秒前
科研通AI2S应助科研通管家采纳,获得10
5秒前
所所应助科研通管家采纳,获得10
6秒前
Owen应助科研通管家采纳,获得10
6秒前
6秒前
lilylwy完成签到 ,获得积分0
6秒前
li完成签到 ,获得积分10
6秒前
可爱的函函应助唐唐采纳,获得10
11秒前
小石头完成签到,获得积分10
13秒前
量子星尘发布了新的文献求助10
17秒前
xiaoxiaoxingchen完成签到 ,获得积分10
17秒前
laohu完成签到,获得积分10
18秒前
风格完成签到,获得积分10
18秒前
大橙子发布了新的文献求助150
20秒前
八点必起完成签到,获得积分10
21秒前
sduweiyu完成签到 ,获得积分10
22秒前
hyf完成签到 ,获得积分10
23秒前
aldehyde应助芊芊要发SCI采纳,获得10
24秒前
Twinkle完成签到,获得积分10
26秒前
Eureka完成签到,获得积分10
28秒前
32秒前
浮熙完成签到 ,获得积分10
39秒前
笔芯完成签到,获得积分10
42秒前
看文献完成签到,获得积分0
44秒前
爱与感谢完成签到 ,获得积分10
46秒前
华仔应助大橙子采纳,获得10
47秒前
小帅完成签到,获得积分10
47秒前
man完成签到 ,获得积分10
48秒前
biofresh完成签到,获得积分10
50秒前
平凡完成签到,获得积分10
54秒前
55秒前
哈利波特完成签到,获得积分10
58秒前
菓小柒完成签到 ,获得积分10
58秒前
basil完成签到,获得积分10
59秒前
大橙子发布了新的文献求助10
59秒前
mammer应助超帅无色采纳,获得10
1分钟前
helloworld完成签到,获得积分10
1分钟前
海洋完成签到,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038157
求助须知:如何正确求助?哪些是违规求助? 3575869
关于积分的说明 11373842
捐赠科研通 3305650
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022